Loading
When a BCMA drug stops working, switching to a drug against a different myeloma protein still produces responses in about two-thirds of patients.
When a BCMA-directed therapy such as teclistamab stops working in multiple myeloma, switching to the GPRC5D-directed bispecific talquetamab is a sequence pairing that still produces responses in a majority of patients. GPRC5D is an independent antigen with different escape mechanisms, so antigen loss through TNFRSF17 deletion, which drives resistance to BCMA agents, does not affect it; T-cell fitness is the limitation the two share. The evidence comes from the cohort of MonumenTAL-1 that enrolled patients previously treated with T-cell redirection, and the RedirecTT-1 combination of teclistamab with talquetamab has shown high response rates including in extramedullary disease. The data are phase 1/2 and phase 3 combination trials are ongoing; the MajesTEC-1 paper on teclistamab links here.
Shares Talquetamab, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares MonumenTAL-1, Talquetamab, Relapsed or refractory multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares GPRC5D, Talquetamab, MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab.
Shares MonumenTAL-1, GPRC5D, Multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares GPRC5D, Talquetamab, Relapsed or refractory multiple myeloma, Multiple myeloma.